PDGFRA and gastrointestinal stromal tumor: A total of 56 patients in NAVIGATOR (all patients with PDGFRA D842V-mutant GIST) and 19 patients in Study 1002 were included in the analysis; of the 56 patients in NAVIGATOR, a subgroup of 38 patients who started avapritinib treatment at 300 mg or 400 mg was also analyzed separately (Fig. 1).